Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.

Authors: Christian F. Singer, Dominik Hlauschek, Georg Pfeiler, Daniel Egle, Rupert Bartsch, Christoph Suppan, Angelika Pichler, Edgar Petru, Richard Greil, Margaretha Rudas, Michael Seifert, Andreas Petzer, Florian Fitzal, Zsuzsanna Bago-Horvath, Martin Filipits, Lidija Soelkner, Christian Fesl, Michael Gnant

Published: 2024-10-04

DOI: 10.1200/jco.2024.42.16_suppl.587

Source: Full article

---

Abstract

587